Investigating the Role of Type I Interferon Signaling on Muscle Disease Using Mouse Models
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.70096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Rita Spathis und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, New York. Hauptthemen laut MEDLINE: Signal Transduction, Interferon Type I, Myositis. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cure JM Foundation, Myositis Association.
Abstract (Originalsprache)
Objective
Dysregulated type I interferon (IFN) signaling contributes to autoimmune myositis pathogenesis. We investigated the therapeutic effects of JAK inhibitors in two mouse models. We also examined how type I IFNs affect muscle vasculature.
Methods
Myositis was induced in major histocompatibility complex class I double transgenic ([TRE‐H‐2K b (H mice)/MCK‐tTA (T mice)] (HT)) female mice at day 21. Mice were randomized into four groups (n = 10–11/group): baricitinib (10 mg/kg), tofacitinib (20 mg/kg), vehicle, and healthy controls. Outcomes included survival, weight, muscle strength, histopathology, and IFN‐stimulated gene expression. To model IFNβ overexpression, C57BL/6 mice received AAV9‐triple muscle‐specific creatine kinase (tMCK)‐IFNβ and were treated with vehicle or tofacitinib (40 mg/kg/day) for 10 weeks (n = 8–13/group).
Results
Tofacitinib—but not baricitinib—significantly reduced IFN scores in mice with severe myositis ( P < 0.05). Survival differed across groups (overall log‐rank P < 0.01), with untreated‐ and baricitinib‐treated HT mice showing shorter survival than BL/6 controls, whereas tofacitinib‐treated mice did not differ from controls. IFNβ overexpression induced muscle inflammation ( P < 0.01), reduced grip strength ( P < 0.0001), and increased the IFN score ( P < 0.0001) and H2Kb ( P < 0.0001) expression.
Conclusion
Tofacitinib reduced the IFN signature, and survival in this group did not differ significantly from healthy controls, whereas untreated and baricitinib‐treated HT mice showed shorter survival; functional improvement was not observed. Our results also show that type I IFN signaling contributes to muscle inflammation and weakness, making it a key driver of muscle damage and thereby reinforcing its potential as a therapeutic target. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, New York.
- Vestal High School, Vestal, New York.
ORCID-Profile: Melissa Morales
Förderung
- Cure JM Foundation
- Myositis Association
Zitieren
APA
Spathis, R., Narvesen, S., Robles Kuriplach, D., Huang, K., Sundar, T., Bagley, E., Parkes, J., Jia, X., Sudhan, N., Guzman, A., Nagaraju, K., & Morales, M. (2026). Investigating the Role of Type I Interferon Signaling on Muscle Disease Using Mouse Models. Arthritis & Rheumatology. https://doi.org/10.1002/art.70096
Vancouver
Spathis R, Narvesen S, Robles Kuriplach D, Huang K, Sundar T, Bagley E, et al. Investigating the Role of Type I Interferon Signaling on Muscle Disease Using Mouse Models. Arthritis & Rheumatology. 2026. doi:10.1002/art.70096
BibTeX
@article{Spathis2026,
author = {Spathis, Rita and Narvesen, Sabrina and Robles Kuriplach, Deeva and Huang, Karen and Sundar, Teja and Bagley, Elizabeth and Parkes, Joanna and Jia, Xinyu and Sudhan, Nandhana and Guzman, Alfredo and Nagaraju, Kanneboyina and Morales, Melissa},
title = {Investigating the Role of Type I Interferon Signaling on Muscle Disease Using Mouse Models},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70096}
}
EUVIMED